IP Library Granted Patent US 10,106,483
Granted Patent B2
US 10,106,483 · App. 15/521,046 · Granted Oct 23, 2018

Process for preparation of azelaic acid

Inventors: Shekhar Bhaskar Bhirud (Mumbai, IN); Kumar Hari Bhushan (Haryana, IN); Prem Chand (Navi Mumbai, IN); Amit Anant Thanedar (Nashik, IN); Amol Anant Kadam (Mumbai, IN); Krishna Baban Narawade (Mumbai, IN)
Assignee: GLENMARK PHARMACEUTICALS LIMITED
C07C51/43
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,106,483
App. No.
15/521,046
Granted
Oct 23, 2018
Kind
B2
Abstract

Provided is a process for preparing azelaic acid.

Claims (14)

1. A process for the preparation of azelaic acid, wherein the level of any single impurity selected from the group consisting of C 3 -C 18 aliphatic mono carboxylic acids, C 3 -C 8 aliphatic dicarboxylic acids, C 10 -C 18 aliphatic dicarboxylic acids, and C 1-5 alkyl esters of azelaic acid, is less than about 0.15% w/w with respect to azelaic acid as measured by HPLC, the process comprising

(a) treating crude azelaic acid containing one or more impurities from the group consisting of C 3 -C 18 aliphatic mono carboxylic acids, C 3 -C 8 aliphatic dicarboxylic acids, C 10 -C 18 aliphatic dicarboxylic acids, and C 1-5 alkyl esters of azelaic acid with an acid; and

(b) treating the treated crude azelaic acid of step (a) with a hydrocarbon solvent and an ester solvent, wherein the hydrocarbon solvent is cyclohexane and the ester solvent is ethyl acetate.

2. The process as claimed in claim 1 , wherein the level of total impurities is less than about 1% w/w with respect to azelaic acid as measured by HPLC.

3. The process as claimed in claim 1 , wherein treating step (b) comprises washing with a hydrocarbon solvent and an ester solvent, or slurring with a hydrocarbon solvent and an ester solvent, or recrystallizing with a hydrocarbon solvent and an ester solvent, or adding to a hydrocarbon solvent and an ester solvent, heating and optionally cooling, or dissolving in a hydrocarbon solvent and ester solvent at a higher temperature optionally followed by cooling, wherein the hydrocarbon solvent is cyclohexane and the ester solvent is ethyl acetate.

4. The process as claimed in claim 1 , wherein the C 3 -C 18 aliphatic mono carboxylic acid is a saturated aliphatic monocarboxylic acid or an unsaturated aliphatic monocarboxylic acid optionally substituted with hydroxy group.

5. The process as claimed in claim 1 , wherein the C 3 -C 18 unsaturated aliphatic monocarboxylic acid is selected from the group consisting of oleic acid, linoleic acid, linolenic acid and ricinoleic acid.

6. The process as claimed in claim 4 , wherein the C 3 -C 18 saturated aliphatic mono carboxylic acid is selected from the group consisting of propanoic acid, hexanoic acid, nonanoic acid, palmitic acid and stearic acid.

7. The process as claimed in claim 1 , wherein the C 3 -C 8 aliphatic dicarboxylic acid is selected from the group consisting of malonic acid, adipic acid, pimelic acid and suberic acid.

8. The process as claimed in claim 1 , wherein the C 10 -C 18 aliphatic dicarboxylic acid is selected from the group consisting of sebacic acid, undecane dioic acid, dodecanedioc acid, tridecanedioic acid and tetradecane dioic acid.

9. The process as claimed in claim 1 , wherein the C 1-5 alkyl ester of azelaic acid is selected from the group consisting of monomethyl azelate and diethyl azelate.

10. The process as claimed in claim 1 , wherein any single impurity selected from the group consisting of pimelic acid, suberic acid, sebacic acid, undecanedioc acid and azelaic acid monomethyl ester in the azelaic acid obtained by the process of claim 1 is not more than 0.15% w/w with respect to azelaic acid as measured by HPLC.

11. The process as claimed in claim 1 , wherein the acid used in step (a) is an organic or inorganic acid.

12. The process as claimed in claim 1 wherein the acid used in step (a) is an inorganic acid.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2019
From: GLENMARK PHARMACEUTICALS LIMITED
To: GLENMARK LIFE SCIENCES LIMITED
Reel/Frame 050179/0351 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2017
From: BHIRUD, SHEKHAR BHASKAR; BHUSHAN, KIMAR HARI; CHAND, PREM; THANEDAR, AMIT ANANT; KADAM, AMOL ANANT; NARAWADE, KRISHNA BABAN
To: GLENMARK PHARMACEUTICALS LIMITED
Reel/Frame 043776/0395 →
Priority Claims (1)
IN 3420/MUM/2014 · Oct 29, 2014 · national
Continuity (1)
Related Publication 20170334825A1 · Nov 23, 2017